Network based approach to drug discovery: A mini review

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 8, 2015, Pages 687-695

  Li, Peng ^a   Fu, Yingxue ^a   Wang, Yonghua ^a  

^a NORTHWEST A F UNIVERSITY   (China)

Author keywords

Drug discovery; Network analysis; Target identification

Indexed keywords

ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; COMORBIDITY; DRUG DESIGN; GENE EXPRESSION; MACHINE LEARNING; PATHOGENESIS; PROTEOMICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ANIMAL; BIOLOGY; DRUG DEVELOPMENT; DRUG INTERACTION; HUMAN; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84929615899     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150219143933     Document Type: Article

References (73)

1. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multitarget drugs: the network approach might help drug design. Trends Pharmacol. Sci., 2005, 26(4), 178-182.
2. Korcsmáros, T.; Szalay, M.S.; Böde, C.; Kovács, I.A.; Csermely, P. How to design multi-target drugs: target search options in cellular networks. Expert Opin. Drug Discov., 2007, 2(6), 799-808.
3. Sams-Dodd, F. Target-based drug discovery: is something wrong? Drug Discov. Today, 2005, 10(2), 139-147.
4. Zhao, S.; Iyengar, R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 505-521.
5. Xie, L.; Xie, L.; Kinnings, S.L.; Bourne, P.E. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 361-379.
6. Barter, P.J.; Caulfield, M.; Eriksson, M.; Grundy, S.M.; Kastelein, J.J.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.-C.; Waters, D.D. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med., 2007, 357(21), 2109-2122.
7. Forrest, M.J.; Bloomfield, D.; Briscoe, R.J.; Brown, P.; Cumiskey, A.M.; Ehrhart, J.; Hershey, J.; Keller, W.; Ma, X.; McPherson, H. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol., 2008, 154(7), 1465-1473.
8. Schönbeck, U.; Libby, P. Inflammation, immunity, and HMG-CoA reductase inhibitors statins as antiinflammatory agents? Circulation, 2004, 109(21 Suppl 1), II18-II26.
9. Yıldırım, M.A.; Goh, K.I.; Cusick, M.E.; Barabási, A.L.; Vidal, M. Drug-target network. Nat. Biotechnol., 2007, 25(10), 1119-1126.
10. Chan, S.Y.; Loscalzo, J. The emerging paradigm of network medicine in the study of human disease. Circ. Res., 2012, 111(3), 359-374.
11. Ideker, T.; Galitski, T.; Hood, L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet., 2001, 2(1), 343-372.
12. Lage, K.; Karlberg, E.O.; Størling, Z.M.; Olason, P.I.; Pedersen, A.G.; Rigina, O.; Hinsby, A.M.; Tümer, Z.; Pociot, F.; Tommerup, N. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol., 2007, 25(3), 309-316.
13. Eckert, H.; Bajorath, J. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. Drug Discov. Today, 2007, 12(5), 225-233.
14. Schneider, P.; Tanrikulu, Y.; Schneider, G. Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. Curr. Med. Chem., 2009, 16(3), 258-266.
15. Byvatov, E.; Fechner, U.; Sadowski, J.; Schneider, G. Comparison of support vector machine and artificial neural network systems for drug/nondrug classification. J. Chem. Inf. Comput. Sci., 2003, 43(6), 1882-1889.
16. Keiser, M.J.; Roth, B.L.; Armbruster, B.N.; Ernsberger, P.; Irwin, J.J.; Shoichet, B.K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol., 2007, 25(2), 197-206.
17. Keiser, M.J.; Setola, V.; Irwin, J.J.; Laggner, C.; Abbas, A.I.; Hufeisen, S.J.; Jensen, N.H.; Kuijer, M.B.; Matos, R.C.; Tran, T.B. Predicting new molecular targets for known drugs. Nature, 2009, 462(7270), 175-181.
18. Lounkine, E.; Keiser, M.J.; Whitebread, S.; Mikhailov, D.; Hamon, J.; Jenkins, J.L.; Lavan, P.; Weber, E.; Doak, A.K.; Côté, S. Largescale prediction and testing of drug activity on side-effect targets. Nature, 2012, 486(7403), 361-367.
19. Jenkins, J.L.; Glick, M.; Davies, J.W. A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. J. Med. Chem., 2004, 47(25), 6144-6159.
20. Jain, A.N. Morphological similarity: a 3D molecular similarity method correlated with protein-ligand recognition. J. Comput. Aided Mol. Des., 2000, 14(2), 199-213.
21. Li, Y.; Tesson, B.M.; Churchill, G.A.; Jansen, R.C. Critical reasoning on causal inference in genome-wide linkage and association studies. Trends Genet., 2010, 26(12), 493-498.
22. Campillos, M.; Kuhn, M.; Gavin, A.-C.; Jensen, L.J.; Bork, P. Drug target identification using side-effect similarity. Science, 2008, 321(5886), 263-266.
23. Bodenreider, O. The unified medical language system (UMLS): integrating biomedical terminology. Nucleic Acids Res., 2004, 32(suppl 1), D267-D270.
24. Iorio, F.; Rittman, T.; Ge, H.; Menden, M.; Saez-Rodriguez, J. Transcriptional data: a new gateway to drug repositioning? Drug Discov. Today, 2013, 18(7), 350-357.
25. Lamb, J.; Crawford, E.D.; Peck, D.; Modell, J.W.; Blat, I.C.; Wrobel, M.J.; Lerner, J.; Brunet, J.P.; Subramanian, A.; Ross, K.N. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 2006, 313(5795), 1929-1935.
26. Iorio, F.; Bosotti, R.; Scacheri, E.; Belcastro, V.; Mithbaokar, P.; Ferriero, R.; Murino, L.; Tagliaferri, R.; Brunetti-Pierri, N.; Isacchi, A. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. U.S.A., 2010, 107(33), 14621-14626.
27. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Nat. Acad. Sci. U.S.A., 2005, 102(43), 15545-15550.
28. Bleakley, K.; Yamanishi, Y. Supervised prediction of drug–target interactions using bipartite local models. Bioinformatics, 2009, 25(18), 2397-2403.
29. Jacob, L.; Vert, J.P. Protein-ligand interaction prediction: an improved chemogenomics approach. Bioinformatics, 2008, 24(19), 2149-2156.
30. Yamanishi, Y.; Araki, M.; Gutteridge, A.; Honda, W.; Kanehisa, M. Prediction of drug–target interaction networks from the integration of chemical and genomic spaces. Bioinformatics, 2008, 24(13), i232-i240.
31. Yamanishi, Y.; Kotera, M.; Kanehisa, M.; Goto, S. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics, 2010, 26(12), i246-i254.
32. Konc, J.; Janežič, D. Binding site comparison for function prediction and pharmaceutical discovery. Curr. Opin. Struct. Biol., 2014, 25, 34-39.
33. Rual, J.F.; Venkatesan, K.; Hao, T.; Hirozane-Kishikawa, T.; Dricot, A.; Li, N.; Berriz, G.F.; Gibbons, F.D.; Dreze, M.; Ayivi-Guedehoussou, N. Towards a proteome-scale map of the human protein–protein interaction network. Nature, 2005, 437(7062), 1173-1178.
34. Stelzl, U.; Worm, U.; Lalowski, M.; Haenig, C.; Brembeck, F.H.; Goehler, H.; Stroedicke, M.; Zenkner, M.; Schoenherr, A.; Koeppen, S. A human protein-protein interaction network: a resource for annotating the proteome. Cell, 2005, 122(6), 957-968.
35. Jeong, H.; Tombor, B.; Albert, R.; Oltvai, Z.N.; Barabási, A.L. The large-scale organization of metabolic networks. Nature, 2000, 407(6804), 651-654.
36. Fell, D.A.; Wagner, A. The small world of metabolism. Nat. Biotechnol., 2000, 18(11), 1121-1122.
37. Duarte, N.C.; Becker, S.A.; Jamshidi, N.; Thiele, I.; Mo, M.L.; Vo, T.D.; Srivas, R.; Palsson, B.Ø. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(6), 1777-1782.
38. Pieroni, E.; de la Fuente van Bentem, S.; Mancosu, G.; Capobianco, E.; Hirt, H.; de la Fuente, A. Protein networking: insights into global functional organization of proteomes. Proteomics, 2008, 8(4), 799-816.
39. Barabási, A.L.; Gulbahce, N.; Loscalzo, J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet., 2011, 12(1), 56-68.
40. Oti, M.; Snel, B.; Huynen, M.A.; Brunner, H.G. Predicting disease genes using protein–protein interactions. J. Med. Genet., 2006, 43(8), 691-698.
41. Navlakha, S.; Kingsford, C. The power of protein interaction networks for associating genes with diseases. Bioinformatics, 2010, 26(8), 1057-1063.
42. Vanunu, O.; Magger, O.; Ruppin, E.; Shlomi, T.; Sharan, R. Associating genes and protein complexes with disease via network propagation. PLoS Comput. Biol., 2010, 6(1), e1000641.
43. Nacher, J.C.; Schwartz, J.M. A global view of drug-therapy interactions. BMC Pharmacol., 2008, 8(1), 5.
44. Kotlyar, M.; Fortney, K.; Jurisica, I. Network-based characterization of drug-regulated genes, drug targets, and toxicity. Methods, 2012, 57(4), 499-507.
45. Wang, X.; Wei, X.; Thijssen, B.; Das, J.; Lipkin, S.M.; Yu, H. Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat. Biotechnol., 2012, 30(2), 159-164.
46. Al-Lazikani, B.; Banerji, U.; Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol., 2012, 30(7), 679-692.
47. Iorio, F.; Saez-Rodriguez, J.; Di Bernardo, D. Network based elucidation of drug response: from modulators to targets. BMC Syst. Biol., 2013, 7(1), 139.
48. Price, N.D.; Papin, J.A.; Schilling, C.H.; Palsson, B.O. Genomescale microbial in silico models: the constraints-based approach. Trends Biotechnol., 2003, 21(4), 162-169.
49. Li, L.; Zhou, X.; Ching, W.K.; Wang, P. Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI-60 cell lines. BMC Bioinformatics, 2010, 11(1), 1471-2105.
50. Folger, O.; Jerby, L.; Frezza, C.; Gottlieb, E.; Ruppin, E.; Shlomi, T. Predicting selective drug targets in cancer through metabolic networks. Mol. Syst. Biol., 2014, 7(1), 501.
51. Gottlieb, A.; Stein, G.Y.; Ruppin, E.; Sharan, R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol., 2011, 7(1), 496.
52. Dudley, J.T.; Deshpande, T.; Butte, A.J. Exploiting drug–disease relationships for computational drug repositioning. Brief. Bioinform., 2011, 12(4):303-311.
53. Hu, G.; Agarwal, P. Human disease-drug network based on genomic expression profiles. Plos One, 2009, 4(8), e6536.
54. Qabaja, A.; Alshalalfa, M.; Alanazi, E.; Alhajj, R. Prediction of novel drug indications using network driven biological data prioritization and integration. J. Cheminformatics, 2014, 6(1), 1.
55. Li, P.; Chen, J.; Wang, J.; Zhou, W.; Wang, X.; Li, B.; Tao, W.; Wang, W.; Wang, Y.; Yang, L. Systems pharmacology strategies for drug discovery and combination with applications to cardiovascular diseases. J. Ethnopharmacol., 2014, 151(1), 93-107.
56. Tao, W.; Xu, X.; Wang, X.; Li, B.; Wang, Y.; Li, Y.; Yang, L. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J. Ethnopharmacol., 2013, 145(1), 1-10.
57. Li, X.; Xu, X.; Wang, J.; Yu, H.; Wang, X.; Yang, H.; Xu, H.; Tang, S.; Li, Y.; Yang, L. A system-level investigation into the mechanisms of chinese traditional medicine: compound danshen formula for cardiovascular disease treatment. Plos One, 2012, 7(9), e43918.
58. Wang, X.; Xu, X.; Li, Y.; Li, X.; Tao, W.; Li, B.; Wang, Y.; Yang, L. Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication. Integr. Biol., 2013, 5(2), 351-371.
59. Hamosh, A.; Scott, A.F.; Amberger, J.S.; Bocchini, C.A.; McKusick, V.A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res., 2005, 33(suppl 1), D514-D517.
60. Goh, K.I.; Cusick, M.E.; Valle, D.; Childs, B.; Vidal, M.; Barabási, A.L. The human disease network. Proc. Natl. Acad. Sci. U.S.A., 2007, 104(21), 8685-8690.
61. Bauer-Mehren, A.; Bundschus, M.; Rautschka, M.; Mayer, M.A.; Sanz, F.; Furlong, L.I. Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases. Plos One, 2011, 6(6), e20284.
62. Sanseau, P.; Agarwal, P.; Barnes, M.R.; Pastinen, T.; Richards, J.B.; Cardon, L.R.; Mooser, V. Use of genome-wide association studies for drug repositioning. Nat. Biotechnol., 2012, 30(4), 317-320.
63. Hidalgo, C.A.; Blumm, N.; Barabási, A.-L.; Christakis, N.A. A dynamic network approach for the study of human phenotypes. PLoS Comput. Biol., 2009, 5(4), e1000353.
64. Lee, D.S.; Park, J.; Kay, K.; Christakis, N.; Oltvai, Z.; Barabási, A.L. The implications of human metabolic network topology for disease comorbidity. Proc. Natl. Acad. Sci. U.S.A., 2008, 105(29), 9880-9885.
65. Sieberts, S.K.; Schadt, E.E. Moving toward a system genetics view of disease. Mamm. Genome, 2007, 18(6-7), 389-401.
66. Park, J.; Lee, D.S.; Christakis, N.A.; Barabási, A.L. The impact of cellular networks on disease comorbidity. Mol. Syst. Biol., 2009, 5, 262.
67. Chiang, A.P.; Butte, A.J. Systematic evaluation of drug–disease relationships to identify leads for novel drug uses. Clin. Pharmacol. Ther., 2009, 86(5), 507-510.
68. Dewey, F.E.; Perez, M.V.; Wheeler, M.T.; Watt, C.; Spin, J.; Langfelder, P.; Horvath, S.; Hannenhalli, S.; Cappola, T.P.; Ashley, E.A. Gene coexpression network topology of cardiac development, hypertrophy, and failure. Circ. Cardiovasc. Genet., 2011, 4(1), 26-35.
69. Ray, M.; Ruan, J.; Zhang, W. Variations in the transcriptome of Alzheimer's disease reveal molecular networks involved in cardiovascular diseases. Genome Biol., 2008, 9(10), R148.
70. Rende, D.; Baysal, N.; Kirdar, B. A novel integrative network approach to understand the interplay between cardiovascular disease and other complex disorders. Mol. BioSyst., 2011, 7(7), 2205-2219.
71. Hu, Z.; Chang, Y. C.; Wang, Y.; Huang, C. L.; Liu, Y.; Tian, F.; Granger, B.; DeLisi, C. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies. Nucleic Acids Res., 2013, 41(1), W225-W231.
72. Csermely, P.; Korcsmáros, T.; Kiss, H.J.; London, G.; Nussinov, R. Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review. Pharmacol. Ther., 2013, 138(3), 333-408.
73. Ideker, T.; Krogan, N.J. Differential network biology. Mol. Syst. Biol., 2012, 8, 565.